Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iohexol + sulfobutylether-beta-cyclodextrin
- Development stage
- Unknown
- Lead developer
- Ligand Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Intraarterial
01
Overview
**iohexol + sulfobutylether-beta-cyclodextrin** is a combination formulation of the iodinated contrast agent iohexol and the excipient sulfobutylether-beta-cyclodextrin (SBECD). This formulation, notably under the investigational brand Captisol Enabled-iohexol, is designed to enhance the safety of iohexol in patients requiring vascular imaging. Iohexol functions as a non-ionic, water-soluble radiocontrast agent, allowing visualization of body structures during X-ray-based procedures by blocking X-ray transmission in iodine-containing tissues. SBECD is added to mitigate nephrotoxicity and reduce contrast-induced acute kidney injury (CI-AKI), especially in high-risk populations. Preclinical evidence demonstrates that SBECD-iohexol reduces renal and myocardial injury by interfering with early apoptotic processes in renal cells and preserving cardiomyocyte integrity during myocardial ischemia. The formulation is currently in phase II clinical trials for prevention of CI-AKI in patients undergoing coronary angiography[1][3].
- Brand names
- Captisol Enabled-iohexol
- Other names
- SBECD-iohexoliohexol-SBECD
Beyond the preview
Go deeper on iohexol + sulfobutylether-beta-cyclodextrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iohexol + sulfobutylether-beta-cyclodextrin.